loop diuretic + finerenone

This combination therapy consists of a loop diuretic (such as furosemide or torsemide) and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA). Finerenone selectively binds to the mineralocorticoid receptor to inhibit overactivation, which is associated with inflammation and fibrosis in the kidneys and heart. Loop diuretics work by inhibiting the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, promoting the excretion of sodium, chloride, and water to manage fluid overload and hypertension. This specific combination is utilized as an active comparator in clinical trials, such as those sponsored by Sarfez Pharmaceuticals, to evaluate the efficacy of new treatments for hypertension and proteinuric chronic kidney disease (CKD).

Other names

finerenone plus loop diureticloop diuretic and finerenone